Inside Inner Cosmos: Digital Pills For The Mind

Inner Cosmos is a young neurotechnology company that wants to turn a tiny implant and a phone into a steady treatment for serious depression rather than another pill to remember every morning. Its vision sits right at the meeting point of psychiatry, engineering, and the ethics of what it means to bring electronics to the edge of the human mind.

What Inner Cosmos Is Trying To Solve

Depression is one of the most common and disabling medical conditions in the world, and many people do not respond well to standard medication or talk therapy even after trying several options. In treatment resistant depression, patients have already failed to improve after at least two classes of antidepressant drugs, and large numbers also drop out of intensive treatments such as clinic based brain stimulation because of time, cost, and side effects.

Inner Cosmos is focused on this difficult group of patients, arguing that the current system asks too much of people who are already struggling just to get through the day. Instead of long hospital visits and medication cycles that may take weeks to show benefit, the company wants depression care to feel more like a quiet background process that simply runs while a person gets on with life.

The Digital Pill Concept

Inner Cosmos describes its device as a digital pill for the mind, borrowing the familiar idea of a daily pill but replacing chemistry with electricity. The system is a brain computer interface that delivers gentle electrical stimulation to mood related networks rather than reading out thoughts or commands in the way that motor control brain computer interfaces do.

The hardware comes in two main pieces. The first is a very small neurostimulator, roughly the size of a fingernail or a penny, implanted under the skin over the skull near the prefrontal cortex behind the hairline on the left side. The second is an external pod that magnetically attaches through the hair, powers the implant, and communicates data to software that the clinician can adjust, often remotely.

How The System Works Day To Day

Implantation is designed as a short outpatient procedure that takes about thirty minutes, after which the device sits under the scalp but outside the brain and skull itself. That placement makes the approach less invasive than deep brain stimulation that requires leads inside the brain tissue, while still giving closer and more focused access than surface treatments delivered through a large coil on the scalp.

After surgery, a patient wears or attaches the pod for scheduled stimulation sessions that are typically around half an hour at a time, with parameters set by a psychiatrist using an online dashboard. The device delivers electrical pulses similar in effect to transcranial magnetic stimulation, but the company emphasizes that this can happen at home under remote supervision, with the pod also streaming data about how the brain is responding over time.

Clinical Trials And Early Evidence

Inner Cosmos is running an early safety and feasibility trial in adults with treatment resistant depression under an Investigational Device Exemption from the United States Food and Drug Administration, one of the first such psychiatric neurotechnology device studies for depression in nearly twenty years. The initial study includes three participants who met strict criteria for resistance to multiple prior therapies, and its primary goals are to show that the procedure and device are safe and practical, with symptom improvement as a secondary outcome.

In a clinical update covering thirty six month outcomes, the company reported that its third participant was now classified as a clinical responder with a fifty four percent reduction in depressive symptoms compared with baseline, and that this improvement was about twenty one percent better than that person’s best previous response to transcranial magnetic stimulation. Independent industry coverage has also noted that the company has completed an early feasibility trial and that the stimulation targets large scale brain networks for mood, attention, and cognitive flexibility in conditions such as treatment resistant depression, obsessive compulsive disorder, and post traumatic stress disorder.

It is important to remember that three patients is a very small sample, that results are reported by the company, and that there is not yet a large randomized controlled trial, but the early data do suggest that the device can be implanted safely and may achieve symptom relief on the same order as transcranial magnetic stimulation in at least some patients.

The People Behind The Technology

Inner Cosmos is led by chief executive officer Meron Gribetz, who has a background in neuroscience, engineering, and spatial computing and previously founded an augmented reality company. The scientific and medical leadership includes neurosurgeon Eric Leuthardt as chief science officer, known for early work in brain computer interface and laser neurosurgery, and psychiatrist Darin Dougherty as chief medical officer, who has implanted many patients with brain devices for depression in academic settings.

The advisory board is chaired by neuroscientist Ed Boyden, a prominent figure in optogenetics and synthetic neurobiology, and the regulatory team is led by Susan Alpert, a former head of device approvals at the Food and Drug Administration and regulatory leader at Medtronic. This group is joined by engineers and medtech entrepreneurs with experience in bioelectrical engineering, advanced chips, and medical device design, as well as board members and investors who have been involved in robotic surgery and other disruptive medical technologies.

Why This Approach Feels Different

One of the strongest arguments in favor of Inner Cosmos is that it tries to blend the potency of device based brain stimulation with the convenience of daily medication. Traditional transcranial magnetic stimulation requires patients to travel to a clinic for many sessions on consecutive days, which is especially hard for someone who is exhausted, anxious, or low on motivation and may also be juggling work, childcare, and cost concerns.

By shrinking the energy delivery hardware to something closer to a coin under the skin and an external pod, Inner Cosmos aims to take that same kind of stimulation and turn it into something that can happen at home, on a schedule that fits the patient rather than the clinic. The company pitches this as solving a major compliance problem, and it also opens the door to continuous long term treatment rather than time limited courses that may wear off, which is a common issue with transcranial magnetic stimulation.

There is also an appealing technical idea here. Because the implant can record and send data while it stimulates, the platform could move toward more adaptive closed loop neuromodulation, where the system tunes stimulation in response to neural patterns linked with mood instead of delivering the same program day after day. That direction mirrors broader trends in advanced deep brain stimulation and next generation brain computer interfaces, which are increasingly described as read and write systems that both measure brain activity and nudge it.

Benefits For Patients And Clinicians

If the device continues to prove safe and effective, several practical benefits stand out. First, the procedure is less invasive than traditional deep brain stimulation since the implant sits above the skull rather than within brain tissue, which should lower surgical risks and recovery time while still providing more precise targeting than non implanted approaches. Second, the ability to deliver stimulation at home avoids the travel burden and disruption of clinic based courses, which could especially help patients with low energy, limited transportation, or rural residence.

For psychiatrists, a programmable system that streams neural and usage data could offer a richer picture of how patients are responding than occasional self report during office visits. Instead of changing a pill and waiting weeks to see if anything improves, a clinician might adjust stimulation intensity, timing, or pattern and watch for shifts in both brain signals and daily symptom scores in closer to real time.

The long term hope, as described by the company and its investors, is that a scalable, outpatient implant that matches or exceeds transcranial magnetic stimulation outcomes could eventually expand access to neuromodulation beyond specialty centers and bring device based treatment to many more of the millions of people living with severe depression.

Real Limitations And Open Questions

Still, it would be naive to treat Inner Cosmos as a solved answer for depression. The clinical evidence so far involves only a handful of participants, which is nowhere near enough to show how safe or effective the device will be across different ages, comorbidities, and subtypes of depression in the real world. Device trials in psychiatry are also complex to run and interpret, since mood can fluctuate over time and sham control conditions must be carefully designed, and none of that work is complete yet for this system.

As with any surgery, even a short scalp procedure carries risks from infection, bleeding, hair loss, or scarring, and living with an implant may not suit everyone both medically and psychologically. There are also practical issues to consider, such as what happens if a patient loses access to follow up care, cannot afford replacement hardware, or wants the device removed after many years, which will only become clear as more people are implanted and followed over longer periods.

Another open question is cost and reimbursement. Inner Cosmos has raised at least ten million dollars in seed funding and is clearly aiming at a large global market for depression care, but there is not yet public information on the final price of the system, how insurers will classify and cover it, or how it will compare economically with long term medication and clinic based neuromodulation. Those details will strongly shape who actually gains access, and whether the technology narrows or widens existing gaps in mental health treatment.

Privacy, Data, And Neurorights

Because Inner Cosmos uses a brain computer interface that both delivers stimulation and collects neural data, it sits inside a broader debate over mental privacy and so called neurorights. Scholars and ethicists point out that as brain computer interfaces and adaptive deep brain stimulation devices mature, they may be able to infer increasingly detailed information about mood, preferences, or even sensitive traits from continuous streams of brain activity, especially when combined with machine learning and background data.

So far, most researchers argue that current systems do not literally read thoughts, and that they mostly reveal patterns such as emotional state or recognition responses rather than inner narrative content. However, the volume and sensitivity of brain data still raise serious concerns about who owns that information, how it is stored, how it may be shared with clinicians, companies, or insurers, and what happens if it is breached or repurposed.

Regulators and advocacy groups are beginning to explore specific protections for neural data, with some countries discussing or adopting neurorights frameworks that highlight mental privacy, cognitive liberty, and identity as special values that should be safeguarded as neurotechnology spreads. Inner Cosmos, like other companies in this space, will need to show not just clinical effectiveness but also strong security, transparent consent processes, and clear boundaries on data use if it wants patients and society to feel comfortable with chips that sit on the skull and quietly talk to phones and cloud servers.

Power, Autonomy, And The Meaning Of Mood

Beyond privacy, psychiatric devices raise questions about agency and self. Adaptive stimulation that reacts to mood related brain states may be helpful, but some ethicists worry that over time it could blur the line between a person’s own emotional life and the patterns set by software and engineers. In closed loop deep brain stimulation, there have already been reports of patients who feel that their mood or sense of self is partly shaped by the device, and similar reflections may arise when people live for many years with a digital pill that shapes how their cortex fires.

At the same time, many patients with severe depression describe the illness itself as a loss of agency, joy, and connection, and they may experience effective neuromodulation as a restoration of control rather than a threat to it. Inner Cosmos will need to listen carefully to patient narratives, not just symptom scores, to understand whether its technology helps people feel more like themselves or introduces new tensions in the relationship between brain, mind, and machine.

Where Inner Cosmos Fits In The Neurotech Landscape

The broader world of brain computer interfaces now ranges from invasive motor prostheses for paralysis to non implanted consumer devices that claim to track focus or relaxation, and public attention has often focused on headline making companies that promise dramatic leaps in human computer fusion. Inner Cosmos sits in a quieter but hugely important niche, using a relatively modest implant to tackle one of the most common and costly psychiatric disorders rather than chasing science fiction visions of direct thought control.

Its design choices reflect that focus. By staying above the skull, limiting itself to stimulation of mood networks, and emphasizing remote medical supervision with a psychiatrist in the loop, the company is positioning its platform as an evolution of established neuromodulation rather than a radical break from medicine. Yet the combination of continuous neural data, mobile delivery, and venture backed scale still gives it a disruptive edge that could reshape how society thinks about depression treatment if the clinical story holds up.

References

Bloomberg. (2024, November 1). Brain tech is here and not as creepy as you think. Bloomberg. https://www.bloomberg.com/opinion/articles/2024-11-01/brain-tech-is-here-and-not-as-creepy-as-you-think

Forbes. (2023, January 9). Inner Cosmos raises 10 million to treat depression with brain computer interface implant. Forbes. https://www.forbes.com/sites/moorinsights/2025/10/28/inner-cosmos-psychiatric-implant-completes-early-feasibility-trial/

Forbes. (2025, October 28). Inner Cosmos psychiatric implant completes early feasibility trial. Forbes. https://www.forbes.com/sites/moorinsights/2025/10/28/inner-cosmos-psychiatric-implant-completes-early-feasibility-trial/

Inner Cosmos. (2025, May 12). Clinical study update Q2 2025. Inner Cosmos. https://innercosmos.ai/2025/05/13/clinical-study-update-q2-2025/

Inner Cosmos. (2025, March 18). Team. Inner Cosmos. https://innercosmos.ai/team/[

Inner Cosmos. (2025, June 30). Inner Cosmos appoints John Freund to board of directors and Greg Schulte as advisory chief technology officer. Inner Cosmos. https://innercosmos.ai/2025/07/01/inner-cosmos-appoints-john-freund-to-board-of-directors-and-greg-schulte-as-advisory-cto

Life Science Market Research. (2025). Meron Gribetz Inner Cosmos private partnering interview at LSI USA. Life Science Market Research. https://www.lifesciencemarketresearch.com/videos/meron-gribetz-inner-cosmos-private-partnering-interview-at-lsi-usa-23

Neurotechnology Center at Columbia University. (2025). Does brain computer interface based mind reading threaten mental privacy. Frontiers in Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC12522429/

GamesBeat. (2025, June 16). Inner Cosmos shows its mildly invasive skull implants can treat depression. GamesBeat. https://gamesbeat.com/inner-cosmos-shows-its-mildly-invasive-skull-implants-can-treat-depression/

Electronic Frontier Foundation. (2025, August 26). Podcast episode protecting privacy in your brain. Electronic Frontier Foundation. https://www.eff.org/deeplinks/2025/08/podcast-episode-protecting-privacy-your-brain